Ionis amends REVEAL Phase 3 for obudanersen in Angelman syndrome to two-arm designSep 29Weekly roundup, 2 itemsIonis PharmaceuticalsobudanersenUpdated
Ionis registers Phase 3 trial of obudanersen for Angelman syndrome due to UPD or imprinting defectsAug 24Trial updateIonis Pharmaceuticalsobudanersen
Ionis posts Q2 2026 results, flags second-half pipeline milestonesJul 29Quarterly updatedonidalorsenIonis Pharmaceuticals
Sign inSign in